The physicochemical stability of BPC-157 across various biological environments may contribute to its apparent safety profile, as the peptide appears to be well-tolerated when administered via different routes including oral, subcutaneous, and intramuscular administration
If IBD, EPI, SIBO, or parasites are driving the poor absorption, those conditions need their own treatment plan running alongside B12 therapy
Lower doses can be used to study minor injuries
TB-500 works through actin regulation
doi: 10.3389/fmolb.2015.00050 Received 19 December 2014 Accepted 19 August 2015 Published 03 September 2015 Volume 2 - 2015 Edited by Laszlo Otvos, OLPE LLC, USA Reviewed by Anja Kunze, University of California, Los Angeles, USA
High doses may cause temporary headaches due to increased NAD+ turnover and mitochondrial activity